ReviewFrontiers in psychiatry2026
Transcranial focused ultrasound stimulation in schizophrenia: current evidence, mechanisms, and future directions.
Review in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Schizophrenia disrupts large-scale brain networks, especially circuits linking cortical and deep subcortical structures. Transcranial focused ultrasound stimulation (tFUS) is an emerging non-invasive neuromodulation technique with the capacity to target deep brain regions with high spatial precision. However, clinical evidence for tFUS in schizophrenia remains limited. Objective: This narrative review synthesizes available preclinical and clinical evidence, with particular attention to mechanisms, safety, stimulation targets, methodological limitations, and translational challenges. Current evidence: In dizocilpine (MK-801) rodent models, tFUS has been reported to reverse cognitive deficits, prevent psychotic-like behaviors, restore parvalbumin-positive GABAergic interneuron markers in the prefrontal cortex, and upregulate NMDA receptor-related signaling. In patients with schizophrenia, early studies suggest that tFUS is feasible and generally well tolerated. Reported targets include the dorsolateral prefrontal cortex (DLPFC) for negative symptoms, the globus pallidus/globus pallidus internus for sensory gating-related circuits, and striatal circuits for auditory hallucinations. Efficacy data remain preliminary. Challenges: Key challenges include bone-conducted auditory confounds that may compromise blinding, incomplete and heterogeneous stimulation-parameter reporting, small sample sizes, short follow-up periods, and limited evidence for durable clinical benefit. Future directions: Future studies should use rigorous sham or auditory-masking procedures, adopt standardized reporting frameworks such as the ITRUSST recommendations, and move from feasibility studies toward larger, circuit-specific, hypothesis-driven trials. Conclusion: Preclinical and early clinical studies suggest that tFUS may have therapeutic potential in schizophrenia, but current evidence is insufficient to support definitive clinical conclusions. Larger well-controlled studies are required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.